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The curative potential of allogeneic hematopoietic cell transplantation (allo-HCT) in the treatment of acute mye-
logenous leukemia (AML) and myelodysplastic syndrome (MDS) relies mainly on the graft-versus-leukemia effect.
Relapse after allo-HCT occurs in a considerable proportion of patients and has a dismal prognosis, with still very
limited curative potential. This review provides an overview of the established and evolving approaches to pre-
venting or treating relapse of AML and MDS after allo-HCT, in the context of novel insight into the biology of
relapse. Established prophylactic measures to prevent relapse include optimized conditioning and graft-versus-
host disease (GVHD) prophylaxis, as well as donor lymphocyte infusion (DLI) for high-risk patients; novel immu-
nomodulatory interventions and maintenance approaches are still experimental. Improved diagnostics can detect
persistent or recurring disease at a molecular level, enabling early preemptive interventions. Established options
include hypomethylating agents and DLI. Standard treatments for hematologic relapse include chemotherapy,
cessation of immunosuppressive treatment, and DLI. Experimental approaches include molecular targeted thera-
pies, novel immunomodulatory treatments, and second allo-HCT. For all interventions, the potential risks, includ-
ing occurrence of GVHD, must be weighed against the benefits individually in each patient. Concurrently,
prevention and treatment of relapse after allo-HCT remain challenging and unmet medical needs.
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for Blood and Marrow Transplantation.BACKGROUND
Epidemiology and Prognostic Factors of Relapse
The incidence of relapse for acute myelogenous leukemia
(AML) and myelodysplastic syndrome (MDS) within the first 2
to 3 years after first allogeneic hematopoietic cell transplanta-
tion (allo-HCT) ranges from 20% to 50%. As for AML and MDS in
general, risk factors for relapse include cytogenetic and
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mutations [13]. In a retrospective analysis. FMS-like tyrosine
kinase 3 (FLT3)-internal tandem duplication (ITD) and the use
of more than 1 course of chemotherapy to achieve a complete
response (CR) were risk factors associated with inferior out-
come, independent of NPM1mutational status [4]. Genetic pro-
filing of MDS in patients undergoing allo-HCT identified
subgroups of patients based on the molecular characteristics of
the disease [5]. The connection between RAS pathway muta-
tions and the risk of relapse, compared with the absence of
RAS pathway mutations, was evident in patients age >40 years
only with reduced-intensity conditioning (RIC) and not with
myeloablative conditioning (MAC) [5]. In contrast, the unfavor-
able prognostic impact of TP53 mutations was comparable in
patients who received an RIC regimen and those who received
anMAC regimen [5]. This information could allow for prognostic
stratification and selection of more intensive or less intensive
conditioning regimens [5].
There is evidence that MRD positivity before allo-HCT has
prognostic value in patients who receive induction chemother-
apy [68]. Based on minimal residual disease (MRD) assessed
by flow cytometry before allo-HCT, the 3-year incidence of
relapsed AML after allo-HCT was similar for MRD-positive
remission (67%) and for morphologically active disease (65%)
but was significantly lower for MRD-negative remission (22%)
[9]. In the future, more sensitive MRD detection may allow for
better identification of patients at increased relapse risk [10].
These data argue to aim for negative MRD before allo-HCT.
However, the toxicity of further therapy, the limited data on
which therapy may be best to achieve this aim, as well as the
delay in achieving a graft-versus-leukemia (GVL) effect argue
against this. Moreover, data on MDS suggest that therapy
before allo-HCT can select for resistant subclones [11] and thus
may contribute to the risk of relapse after allo-HCT. Therefore,
in AML as well as in MDS, currently no recommendation can
be made to treat for negative MRD in any situation. According
to the European LeukemiaNet recommendations for patients
with newly diagnosed AML and an indication for allo-HCT, a
CR without consideration of MRD should be achieved [12]. In
MDS, cytoreductive therapy before allo-HCT is recommended
if the bone marrow blast count exceeds 10%. In MDS, cytore-
ductive therapy before allo-HCT is recommended depending
on the bone marrow blast count [13]. The blast count cutoff for
nonmyeloablative allo-HCT is 5% in most institutional and
Blood and Marrow Transplant Clinical Trials Network (BMT
CTN) studies. Long-term survival in patients with relapse of
AML and MDS after allo-HCT is poor, ranging from 10% to 30%.
Factors associated with better survival include duration of
remission after first allo-HCT of >6 months, absence of graft-
versus-host disease (GVHD), and low blast count at relapse
[14].
In cases of relapse after allo-HCT, up to 50% of patients have
cytogenetic or molecular evolution of their disease [15]. A
recent analysis in patients with MDS suggested that relapse
after allo-HCT is driven by subclones evolving from founding
clones existing before allo-HCT but harboring new aberrations
[11], arguing for clonal evolution. Thus, a complete workup
similar to that performed at initial diagnosis is recommended
to allow detection of potentially new targetable aberrations.
Biology of Relapse
Given the proven GVL effect, relapse after allo-HCT in AML
and MDS must occur from persisting leukemic cells, particu-
larly leukemia stem cells [16] which have escaped the cytotox-
icity of conditioning and allogeneic immune response. Alongwith immunogenic peptides, T cells recognize structural epito-
pes of non-self HLAs, which leads to leukemia elimination. In
agreement with a role of HLA molecules in leukemia elimina-
tion, deletion of mismatched HLA has been found in leukemia
cells on post-allo-HCT relapse [17]. HLA loss has been observed
after haploidentical allo-HCT [18,19] and after allo-HCT from
an unrelated donor [20,21]. This HLA deletion does not reduce
the abundance of other HLA class I molecules. The reported
incidence of HLA loss in relapse after allo-HCT is higher in the
haploidentical setting compared with the matched unrelated
donor setting (reviewed in [22]). Treating relapse based on
HLA loss with an allograft with a new mismatched haplotype
may improve outcomes after second allo-HCT for a relapsed
hematologic malignancy [23].
Along with T cells, the natural killer (NK) cell compart-
ment plays an important role for relapse prevention, because
NK cells are activated owing to the absence of self-HLA class I
molecules on malignant cells. Reduced expression of HLA
class II molecules has been observed in, for example, chronic
myelogenous leukemia [24], Hodgkin lymphoma, aggressive
B cell lymphomas [25,26], and relapsed leukemia in patients
without genomic HLA loss [27,28]. Reduced expression of
HLA class II molecules has been shown to promote leukemia
relapse, which could be counterbalanced by IFN-g treatment
to enhance HLA expression [29]. Leukemia cells that cause
relapse also may up-regulate inhibitory immune checkpoint
molecules to escape from the allogeneic T cells. Increased
expression of PD-1, TIGIT, and KLRG-1 on tumor-reactive
CD8+ T cells has been found in relapsed patients [30], and
PD-1/PD-L1 interactions have been shown to promote T cell
impairment in patients who relapse after allo-HCT [31]. These
observations provide a rationale for immunotherapy with
blocking antibodies to treat relapse after allo-HCT. Clinical
data show that CTLA4 blockade in AML relapse can lead to
impressive responses connected to the presence of perforin-
producing donor T cells [3234].
In contrast to CTLA4 blockade, the role of PD-1 inhibition in
AML relapse is unclear. Case studies have shown potential
activity of anti-PD1 immunotherapy for AML relapse [35], but
prospective trials are needed to validate these preliminary
data. Myeloid neoplasms with specific mutations are poten-
tially immunogenic diseases, because alloreactive T cell for
mutated genes, such as JAK2, have been reported [36]. An addi-
tional mechanism may be immune escape induced by onco-
genic mutation; for example, mutated JAK2V617F causes higher
PD-L1 levels and consecutive vulnerability to anti-PD-1 immu-
notherapy [37]. Along with the action of immune checkpoint
molecules as negative regulators of T cell activation, anti-
inflammatory cytokine production can interfere with effective
antileukemia immune responses [38]; for example, IL-4 and
IL-10, which may interfere with immune responses, have been
found to be produced by AML cells [39]. Furthermore, it has
been shown that chronic myelogenous leukemia cells produce
TGF-b [38], which reduces the expression of CIITA and also
MHC-II [40]. The reduction in MHC-II expression will reduce
the ability of the immune system to recognize leukemia cells.
In agreement with an important role for MHC class II mole-
cules, in one study several class II genes (HLA-DPA1, -DPB1,
-DQB1, and -DRB1) were significantly reduced in patients with
AML at relapse after allo-HCT compared with those seen in
paired samples obtained at presentation [28].
In addition to the production of anti-inflammatory factors,
myeloid leukemia cells may reduce the production of proin-
flammatory cytokines, such as IL-2, IFN-g, and IL-15 (reviewed
in [22]). Although healthy myeloid progenitor cells secrete IL-
e130 R. Zeiser et al. / Biol Blood Marrow Transplant 25 (2019) e128e14015 [41], some myeloid leukemia subtypes are associated with
down-regulated IL-15 production [42]. IL-15 promotes the sur-
vival and activation of alloreactive T cells [43], which can be a
disadvantage for leukemia cells.
Previous studies have shown an association between
decreased IL-15 in the blood and relapse [44]. Taking this into
account, strategies have been developed to use IL-15 for the
enhancement of GVL effects; for example, a clinical study that
analyzed the effect of an IL-15 superagonist complex showed
that this intervention led to clinical responses and NK cell
expansion [45].
To escape the allogeneic immune response, some leukemia
subtypes may produce enzymes that change the metabolism.
Examples include indoleamine 2,3-dioxygenase-1 (IDO1) [46],
arginase [47], CD39 [48], and CD73 [49]. The enzyme CD73
converts adenosine-monophosphate into adenosine, a metab-
olite that inhibits the function of T cells and dendritic cells. In
agreement with this, the rejection of leukemia cells after allo-
HCT was enhanced in mice with a genetic deficiency of CD73
[50]. Furthermore, it has been shown that T cell lymphoma
cells are rejected in A2aR-null mice in a CD8-dependent man-
ner but are not controlled in WTmice [51]. The effect of adeno-
sine is mediated through the A2aR and A2b receptors on innate
and adaptive immune cells. Inhibiting agents for A2aR cur-
rently in clinical trials include CPI-444 (ClinicalTrials.gov iden-
tifier NCT02655822), PBF-509 (NCT02403193), MK-3814
(NCT03099161), and AZD4635 (NCT02740985), among others.
The A2aR inhibitors are mostly combined with immune check-
point inhibitors. The enzyme CD39 can interfere with immune
activation in AML at primary diagnosis [48].
Last but not least, accumulating evidence demonstrates a
role of the bone marrow microenvironment in the biology of
MDS and AML and relapse after allo-HCT. In animal models,
specific alterations in cells of the bone marrow stroma particu-
larly affecting miRNAmetabolism can elicit an MDS-like malig-
nancy with ensuing AML [52]. In addition, in humans,
alterations in patient-derived bone marrow stroma cells that
propagate MDS and AML by affecting miRNA content [53] as
well as the expression of cytokines [5456] have been
described. These alterations of stroma cells are likely induced
by their interaction with MDS and AML cells [54,55] and
appear to be reversible [57]. Whether such alterations also
contribute to relapse remains speculative; however, a specific
role of bone marrow stromal cells in conferring resistance to
AML cells through induction of antiapoptotic and pro-prolifer-
ative signals in AML cells [58,59] has been reported recently. In
animal models, the engraftment of hematopoietic stem cells
(HSCs) after transplantation is strongly supported by cotrans-
planted stroma cells, which compensate for the damage caused
by the conditioning [60]. The finding that normal HSCs and
leukemia stem cells (LSCs) occupy the same niche and that
HSCs can outperform LSCs [61] supports the concept that mod-
ification of the bone marrow stroma can improve the efficacy
of allo-HCT. In accordance with this idea, preclinical data have
been published suggesting that interference with the interac-
tion of leukemia and stroma cells may provide a new approach
to improve treatment [62]. However, clinical data on the spe-
cific use to prevent or treat relapse after allo-HCT are lacking.
PREVENTION OF RELAPSE
Conditioning Intensity
Several studies have explored the effect of the intensity of
the conditioning regimen on relapse rate and overall survival
(OS) in patients with AML and MDS. A prospective randomized
Phase III study by the European Society of Blood and MarrowTransplantation showed no significant differences in 2-year
progression-free survival (PFS) or OS in patients with MDS and
secondary AML after RIC compared with MAC [63]. In another
prospective randomized Phase III study, relapse rate and
3-year PFS were not significantly different between patients
with intermediate-risk AML and those with high-risk AML
after RIC compared with MAC [64]. However, in both studies, a
trend (albeit not a significant one) toward reduced PFS was
seen with RIC.
In contrast, a randomized study of younger (<65 years)
patients with AML and MDS showed a significantly increased
relapse rate in the RIC group. Relapse-free survival was 47.3%
with RIC versus 67.8% with MAC (P < .01) [65]. At 18 months,
OS was 67.7% for patients in the RIC arm versus 77.5% for those
in the MAC arm (P = .07). Transplantation-related mortality
was 4.4% with RIC versus 15.8% with MAC (P = .002) [65].
Taken together, the findings of the foregoing studies sug-
gest that the intensity of conditioning contributes to disease
control in AML and MDS. This idea is supported by retrospec-
tive data in patients with AML with active disease at the time
of HCT, in whom MAC yielded similar PFS and OS compared
with sequential chemotherapy followed by RIC [66]. This sug-
gests that total cytotoxic activity is relevant for disease control.
Therefore, based on the current data, intensity of condition-
ing should be chosen based on patient age, comorbidities, and
disease status.Intensity and Duration of Immunosuppression for GVHD
Prophylaxis
The intensity of immunosuppression appears to have an
impact on the GVL effect, as it has been shown for other enti-
ties that reduction of immunosuppression in patients with
positive MRD reduces the risk of overt relapse [67,68]. Specifi-
cally, in patients with AML, an association between the dose
and duration of cyclosporin A treatment with risk of relapse
has been reported [69].
Data from 3 prospective randomized studies on the use of
antithymocyte globulin (ATG) during conditioning have been
reported. Two open-label randomized studies showed that in
vivo T cell depletion with anti-T lymphocyte globulin (ATLG;
formerly Fresenius, now Neovii) reduces chronic GVHD
(cGVHD) in the setting of related and unrelated donors, respec-
tively [70,71]. A third prospective, double-blind phase III trial
also investigating ATG (Neovii) in MUD MAC reported reduc-
tions in grade II-IV acute GVHD (aGVHD; 23% versus 40%;
P = .004) and moderate to severe cGVHD (12% versus 33%; P <
.001) in ATLG recipients but no difference in moderate-severe
cGVHD-free survival between ATLG and placebo [72]. Rather,
2-year PFS (47% versus 65%; P = .04) and OS (59% versus 74%;
P = .034) were reduced in the ATG group, and ATG maintained
a negative impact on PFS and OS in multivariate analysis [72].
The reasons for the discrepancies between these trials are not
yet clear, and more data on the subgroups in the latter trial are
needed.
Other methods of GVHD prophylaxis, including alemtuzu-
mab, in vitro T cell depletion, and post-transplantation cyclo-
phosphamide, may have an impact on the GVL effect;
however, longer follow-up is needed to allow for valid conclu-
sions.
Based on these data, immunosuppression including ATG
generally should be chosen depending on the availability of a
related or unrelated donor, HLA match, and relapse risk. Spe-
cifically, the use of ATG is still recommended; however, cau-
tion should be applied regarding a possible ATG-related
R. Zeiser et al. / Biol Blood Marrow Transplant 25 (2019) e128e140 e131increased risk of relapse, weighed against the risk of GVHD-
related complications.
Maintenance Therapy to Prevent Relapse
For patients with MRD-positive AML heading to transplan-
tation, one option is to treat them into remission before
allo-HCT, which may incur a higher toxicity and increase non-
relapse mortality (NRM) after allo-HCT. Conversely, the con-
cept of controlling or eradicating residual LSCs after allo-HCT
with maintenance therapy is intriguing. However, such ther-
apy also carries the risk of reducing the GVL effect. Moreover,
drugs established in the pretransplantation setting may result
in much more pronounced side effects in the post-transplanta-
tion situation. Thus, well-designed studies are needed to estab-
lish maintenance approaches in patients with AML/MDS.
Conclusive data are not yet available, and thus no standard
maintenance therapy for AML or MDS after allo-HCT can be
currently recommended as standard of care. Several mainte-
nance approaches show promise, but further data from ongo-
ing or future clinical trials are needed to assess their potential.
Immunomodulators
Maintenance therapy with lenalidomide for patients with
AML or MDS who achieved remission after allo-HCT has been
associated with a high rate of severe GVHD [73]. In a Phase I/II
study, maintenance therapy with the deacetylase inhibitor
panobinostat for patients with high-risk MDS/AML in CR after
allo-HCT led to a 2-year survival of 81% and a relapse-free sur-
vival of 75% [74]. These findings are promising, and a larger
follow-up study is currently underway. A synergistic effect of
the combination of 5-azacytidine and lenalidomide as postre-
mission maintenance outside of allo-HCT was reported in a
phase I trial [75], and randomized trials in the prophylactic set-
ting are ongoing (Clinical Trials.gov identifier NCT00887068).
Tyrosine Kinase Inhibitor Maintenance for FLT3-ITD AML
Clinical data on maintenance with midostaurin for FLT3-ITD
AML show a low 1-year relapse rate of 9.2% [76]. Several early-
phase studies and case reports have reported evidence for the
efficacy of sorafenib maintenance therapy in patients with
FLT3-ITD AML [7780]. The results of a placebo-controlled
randomized phase II trial (SORMAIN trial) indicated a higher
relapse-free survival in the sorafenib group compared with the
placebo group [81]. Phase I data on quizartinib show the feasi-
bility of tyrosine kinase inhibitor (TKI) maintenance after allo-
HCT [82]. A prospective Phase III randomized trial using gilteri-
tinib versus placebo for patients with FLT3-ITD+ AML as main-
tenance after allo-HCT is currently ongoing [83].
Prophylactic Donor Lymphocyte Infusion and Other Cellular
Therapy
General Considerations
Donor lymphocyte infusion (DLI) is a cellular product of
mononuclear donor cells with a defined CD3+ T cell content.
DLI is derived by apheresis from the original HSC donor either
as aliquots from the original G-CSF-mobilized peripheral blood
stem cell (PBSC) product or by an additional unstimulated leu-
kapheresis. Several reports suggest that DLI harvested after
G-CSF stimulation from the original stem cell product is effec-
tive in eliciting a GVL effect [8486]. Data on direct compari-
son of G-CSF-mobilized DLI versus DLI from unstimulated
leukapheresis are sparse, but a retrospective analysis in 67
patients suggested similar activity of both DLI sources [85].
Owing to logistical and feasibility considerations, DLIs are
mostly cryopreserved and transfused after thawing. Newapproaches to enhance the efficacy of DLIs or reduce their tox-
icity have been explored [87,88], but data are insufficient for
clinical recommendations.
Prophylactic DLI is applied in the presence of CR to induce a
GVL effect and/or improve donor chimerism. Multiple studies
indicate that AML and MDS are sensitive to a DLI-induced GVL
effect [89]; however, convincing prospective randomized data
are lacking.Available Data on Efficacy, Timing, and Dosing
An alemtuzumab-based T cell-depleted (TCD) study
reported an effect of prophylactic DLI to improve PFS and OS
[90]. A trial by the National Institutes of Health using add-
back donor T cell infusion following ex vivo TCD HCT reported
an OS of 58%, DFS of 46%, relapse rate of 40%, and NRM of 20%,
at a median follow up of 4 years [91]. The incidence of grade
II-IV aGVHD was 39% and that of cGVHD was 36% [91]. In a
prospective study, 19 children with an HLA-matched or -mis-
matched unrelated PBSC transplant received T cell add-back
following TCD allo-HCT, and the risk of grade II-IV aGVHD
and extensive cGVHD was 16% and 0%, respectively [92]. All
patients engrafted, and NRM at 1 year was 6%, with a 1-year
OS of 82% [92].
Less data are available for non-TCD settings. In an initial
prospective study, repeated prophylactic DLI in escalating
doses starting at day +120 post-HCT were shown to be feasible
in patients with AML and MDS with high relapse risk [93,94].
Besides the presence of a complete response, criteria for appli-
cation of prophylactic DLI were no immunosuppressive medi-
cation for >30 days, lack of infection, and lack of GVHD.
Relapse and cGVHD occurred in 30% and 20% of DLI-treated
patients, respectively. A subsequent retrospective analysis was
performed in an extended cohort of patients with AML who
met the same criteria and received escalating doses of prophy-
lactic DLI (starting at .5£ 106/kg for related donor graft recipi-
ents and 1£ 106 for unrelated donor graft recipients). Results
were compared with those of a matched control cohort. In the
DLI group, 9% of patients developed grade II-IV aGVHD and
11% developed extensive cGVHD. At 7 years, OS was 67% in the
DLI group compared with 31% in controls (P < .001), owing to
a lower relapse risk in the DLI group (22% versus 53% in con-
trols; P = .004) [95].
In a prospective study, DLI was applied prophylactically
concurrent with immunosuppression within 60 days in 50
patients with high-risk acute leukemia after related donor
allo-HCT [96]. The incidence of cGVHD was higher in the DLI
group compared with controls (n = 73) (38% versus 17%;
P = .021). However, DLI was associated with a lower 2-year
cumulative relapse rate (46% versus 66%; P = .02) and a higher
3-year OS (36% versus 11%; P = .001). Further prospective [97]
and retrospective [98] studies have reported on the feasibility
of prophylactic DLI in AML/MDS with high relapse risk.
Prophylactic DLI also has been reported to be feasible in
haploidentical or mismatched donor HCT [99]. In a retrospec-
tive analysis, patients receiving DLI including continued immu-
nosuppressive medication (n = 61) compared with controls
without DLI (n = 27) had a lower 2-year cumulative relapse
rate (36% versus 55%; P = .017) and better estimated 3-year OS
(31% versus 11%; P = .001) [100].
An open issue is the optimal timing of prophylactic DLI. In a
prospective analysis, DLI was started as early as day 21 with
concurrent cyclosporine A administration. The different set-
tings and schedules in the published studies preclude clear rec-
ommendations and call for further evaluation.
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MDS is to combine DLI with maintenance therapies, using
donor lymphocytes that have been manipulated to enhance
their GVL efficacy while reducing the risk of GVHD.
Based on these data, the following approach for prophylac-
tic DLI in AML and MDS after T cell-replete allo-HCT can be rec-
ommended. DLI should be considered based on the expected
risk of relapse and GVHD but should be applied only if domi-
nant overall donor chimerism has been achieved (if recipient
chimerism is dominant, DLI may be less effective), GVHD and
severe infections are absent, and immunosuppression has
been stopped for >4 weeks. Thus, assessment of remission sta-
tus and chimerism as well as clinical evaluation is necessary
before DLI. A starting dose of .1 or 1£ 106 CD3+ cells/kg body
weight in allo-HCT recipients with unrelated or related donor
grafts, respectively, carries a low risk of GVHD. DLI can be
repeated every 4 to 12 weeks in doses escalated by 5- to 10-
fold as long as GVHD does not occur. Representative studies of
prophylactic DLI in AML and MDS are summarized in Table 1.
Given the limited data, no recommendations can be made for
DLI in haploidentical allo-HCT or for early DLI with concurrent
immunosuppression.TREATMENT OF MRD AND OVERT RELAPSE
Relapse incidence is highest within the first 2 years after
allo-HCT, and survival is better when incipient relapse is
detected early. Therefore, regular monitoring for MRD
markers, including chimerism, is recommended. In overt AML/
MDS relapse, reduction of immunosuppression can result in a
response and even CR in some cases [1218]. Several other
approaches to “actively” treat AML/MDS relapse after allo-HCT
have been proposed. Data on different strategies for treatment
of overt relapse are sparse. Strategies to treat relapse are sum-
marized in Figure 1.
Hypomethylating AgentsPreclinical Evidence Supporting a Role of Hypomethylating Agents
in Antitumor Immunotherapy
Pharmacologic inhibition of DNA methylation in malignant
cells can activate the expression of endogenous retroviruses,
leading to type II interferon responses [101,102]. In addition,
treatment with 5-aza-20-deoxycytidine was found to induce
the expression of cancer/testis antigens (CTAs) in AML cell
lines [103]. One CTA, NY-ESO-1, converted the cell lines sus-
ceptible to antigen-specific recognition by CD8+ T cell clones
[103]. These findings provide a therapeutic rationale for com-
bining DNA methylation inhibitors with allogeneic immunity
to treat relapse.Table 1
Selected Studies on Prophylactic DLI in AML/MDS
Condition (Number of Patients) and Study
Type
Strategy
AML/MDS (N = 46); retrospective, matched
control group
Prophylactic DLI at 120 d post-allo-
IS stopped for >30 d, no GVHD, and n
infections)
AML/ALL (N = 89); retrospective, matched-
pair
Prophylactic DLI <1 yr after allo-HCT
preceding GVHD
IS indicates immunosuppressive medication.Preemptive Treatment (Treatment of Incipient Relapse)
In a prospective uncontrolled Phase II study, treatment with
5-azacytidine in patients with elevated MRD markers induced
an increase in donor chimerism or a decline in MRD [104].
5-azacytidine treatment may be combined with DLI [104].
Based on these data and the labeling of azacytidine in Europe,
preemptive use of 5-azacytidine might be considered in
patients with AML or MDS and decreasing donor chimerism.Therapeutic Treatment (Treatment of Hematologic Relapse)
The combination of azacytidine and DLI to treat relapse after
allo-HCT has been shown to have efficacy in clinical applications,
including a Phase I study [105], a Phase II study [106], and several
retrospective analyses [106109]. A retrospective analysis in
patients receiving azacytidine in combination with DLI reported
an overall response rate of 33% and a 2-year OS of 29% [108].
GVHD was seen almost exclusively in patients receiving DLI.
Molecular relapse only, diagnosis of MDS, and low marrow blast
count at the time of relapse were associated with better OS.Which
patients will require a second allo-HCT for long-term disease con-
trol after achieving a first remission postrelapse is currently
unclear.
Less data are available for decitabine, but a retrospective
study on the use of decitabine in combination with DLI showed
a response rate of 25%, including patients with previous azacy-
tidine failure, and a 2-year OS of 11% with low rates of aGVHD
and cGVHD [110].
In a retrospective center analysis, a direct comparison of
intensive chemotherapy with hypomethylating agents showed
better OS with intensive chemotherapy [111]; however this
finding needs confirmation in a prospective trial. Induction of
PD-L1 expression by hypomethylating agents has been
reported [112]; therefore, up-regulation of PD-L1 expression
on blasts of patients with AML/MDS who have progressed after
therapy with hypomethylating agents may be a cause of
immune evasion promoted by the treatment itself. In overt
relapse, hypomethylating agents, in combination with DLI if
possible, may be considered in a subgroup of patients and can
be recommended especially for patients who might not be eli-
gible for more aggressive remission induction.TKI for FLT3-ITD AML Relapse
Preclinical Evidence Supporting a Role of TKI in Antitumor
Immunotherapy
Sorafenib may increase the immunogenicity of leukemia
cells via induction of IL-15 production by the cells, thereby
enhancing T cell activation, as shown in AML mouse models
[42]. FLT3-ITD is associated with induction of Activating tran-
scription factor 4 (ATF4), which blocks the expression of IL-15.Main Findings Reference
HCT (if
o
Improved survival with DLI compared with controls:
7-yr OS, 67% versus 31% (P < .001)
[95]
if no Improved survival with DLI compared with controls
only for high-risk AML (cytogenetic risk or allo-HCT
in active disease): 5-yr OS, 70% versus 40% (P = .036)
[135]
Figure 1. Currently known targets and drugs to enhance the GVL effect as an approach to prevent or treat relapse of AML/MDS after allo-HCT. Alloreactive T and NK
cells can be activated via anti-CTLA4 and anti-PD1 immune checkpoint inhibition, as well as IFN-a. Leukemia cells can be rendered more immunogenic via (1)
INF-a-induced up-regulation of MHC class II, (2) hypomethylating agents leading to the expression of neoantigens, and (3) TKIs like sorafenib inducing IL-15 produc-
tion. Proliferation of leukemia cells can be inhibited by TKIs, hypomethylating agents, and chemotherapy.
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motes IRF7-induced IL-15 transcription [42].Therapeutic Treatment
Recent unprecedented evidence was provided from a retro-
spective cohort of 29 patients with FLT3-ITD+ AML who
relapsed after allo-HCT [113]. Six of the 29 patients (21%)
achieved sustained CR with sorafenib monotherapy. Excluding
1 patient who underwent a second allo-HCT, 4 of these
patients were in treatment-free remission for a median of
4.4 years. With a median follow-up after relapse of 7.5 years,
these data suggest for the first time that FLT3-ITD inhibition
alone can induce long-term disease control and conditional
cure in patients who relapse after allo-HCT [113].
Several case series and retrospective studies in patients
with FLT3-ITD+ AML relapse after allo-HCT have shown
impressive responses to sorafenib, including increased long-
term survival [114117]. Some patients have received sorafe-
nib in combination with DLI or azacytidine [118]. In a retro-
spective analysis, treatment of FLT3-ITD+ AML relapse after
allo-HCT with sorafenib and DLI was found to be superior to
treatment with DLI alone [42].
The clinical evidence of a synergism between FLT3 inhibi-
tion and alloimmunity against leukemia cells motivated stud-
ies in a mouse model, which showed that FLT3 inhibition
combined with T cell infusion can lead to complete elimination
of leukemia cells. Mechanistically, FLT3 inhibition reduced
expression of the transcription factor ATF4. ATF4 normally
blocks interferon regulatory factor 7 (IRF7) activation, and this
effect was antagonized by the FLT3 inhibition. Removal of the
ATF4-mediated blockade allowed IRF7 activation and caused
IL-15 transcription in the leukemia cells, which were then
eliminated by donor T cells [42]. Increased IL-15 was detected
in the blood of responding patients and caused an increase in
mitochondrial spare respiratory capacity in T cells, consistentwith previous reports indicating that IL-15 causes mitochon-
drial reprogramming in T cells [119,120].
The FLT3 inhibitors sorafenib and midostaurin have broad
inhibitory activity against multiple kinases, and whether this
property has an advantage over selective FLT3 inhibition
remains an open question.
Despite the promising data, however, no clear recommen-
dation on the use of TKIs for post-allo-HCT relapse of FLT3-
ITD+ AML can be made owing to the lack of a randomized, pla-
cebo-controlled Phase III trial.
Immunomodulatory Treatment with Lenalidomide
Case studies have reported that lenalidomide treatment can
eliminate leukemia cells in relapsed AML after allo-HCT [121].
However, data are sparse, and no recommendation can be
made on the use of lenalidomide for relapsed AML/MDS after
allo-HCT.
CTLA4/PD1/PD-L1 Inhibition
Based on the impressive success of immune checkpoint
inhibition in solid cancers and the potential to enhance the
GVL effect, the treatment of hematologic cancers with this
immunotherapy is an attractive approach. A recent study of 28
patients with AML, MDS, or another hematologic malignancy
who relapsed after allo-HCT and were treated with ipilimumab
(anti-CTLA-4 antibody) found an overall response rate of 32%,
with a 23% CR and 9% PR and a 14% rate of GVHD [34]. In addi-
tion, 27% of the nonresponding patients according to standard
criteria had a decreased tumor burden. Intriguingly, CR
occurred in 4 patients with extramedullary AML [34]. Similarly,
2 smaller studies reported responses in patients treated with
ipilimumab for relapse of hematologic malignancy after allo-
HCT [32,33].
In contrast to the findings for anti-CTLA-4 immunotherapy,
higher rates of severe aGVHD and cGVHD rates (up to 55%)
have been reported with anti-PD1 immunotherapy after allo-
Table 2
Selected Studies on the Use of Preemptive DLI
Condition (Number of Patients) and
Study Type
Strategy Main Findings Reference
AML/MDS (n = 69) and ALL (total
n = 101); retrospective, nonrandomized,
single center
Preemptive CTx plus DLI, followed by IS for
patients with positive MRD
Entire group: 3-yr PFS, 51.7%; aGVHD, 9%;
moderate/severe cGVHD, 51%
[128]
AML/MDS (n = 529) and ALL (total
n = 814); prospective, nonrandomized,
monocenter
If MRD-positive and no GVHD: DLI (plus IL-2,
partially with CTx before DLI; n = 56) or IL-2 only
(n = 49); comparison with MRD-negative patients
(n = 709)
Entire group: improved OS and reduced relapse
rate with DLI compared with IL-2 only; 3-yr OS:
MRD-negative, 66%; DLI, 58%; IL-2 only, 28%
[136]
Pediatric AML (n = 71); prospective,
nonrandomized, multicenter
Preemptive DLI (n = 13) versus stop IS-only (n = 7)
in patients with mixed chimerism (n = 20)
Entire group: long-term PFS only with DLI (46%; 6
of 13) but not in stop IS-only 0% (0 of 7)
[68]
AML/MDS (n = 44) and ALL (total n = 80);
retrospective, matched-pair, single
center
If MRD-positive, DLI (n = 11) versus CTx, followed
by DLI (n = 33) with prophylactic IS after DLI
Entire group: similar 2-yr OS for DLI (69%) and
CTx + DLI (78%; P = .36)
[124]
CTx indicates chemotherapy.
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anti-PD1 antibody nivolumab for relapse after allo-HCT [35].
The sparse data preclude any recommendation regarding the
off-label use of ipilimumab or anti-PD-1/PD-L1 in AML/MDS
relapse after allo-HCT, however.
Cellular Therapy
Given the strong GVL effect in myeloid neoplasia, DLI may be
a viable approach in the preemptive setting—that is, in the pres-
ence of positive MRD or recipient chimerism—as well as in the
therapeutic setting for overt relapse of AML and MDS. Several
nonrandomized and retrospective studies have demonstrated
the efficacy of preemptive DLI [123]; selected studies are sum-
marized in Table 2. As for prophylactic DLI, immunosuppressive
drugs were applied concurrently with DLI in some studies [124],
but the data are heterogeneous, and further trials are needed.
A response of overt AML/MDS relapse to therapeutic DLI has
been reported in a prospective study and several retrospective
studies [94,125,126]. Selected studies are summarized in Table 3.
Available data suggest that DLI in the preemptive setting
results in better response than DLI administered for overt
relapse [127]. Given the biology of the GVL effect, preemptive
or therapeutic DLI is indicated only if engraftment, as indicatedTable 3
Selected Studies on the Use of Therapeutic DLI
Condition (Number of Patients)
and Study Type
Strategy
AML (n = 399) retrospective, multicenter DLI (n = 171) versus no-DLI (n = 228
combined with CTx in both groups
AML (n = 263); retrospective, multicenter Various strategies, including CTx, D
second allo-HCT or their combinati
relapse after RIC allo-HCT
AML/CML/MDS (n = 65); prospective, non-
randomized, single center
Cytarabine-based CTx followed by D
Pediatric AML (n = 123); ALL (n = 157), and
biphenotypic AL (n = 8); retrospective,
multicenter
CTx alone (n = 108) versus DLI alon
versus BSC (n = 67) versus CTx follo
either DLI (n = 30) or second allo-H
AML (n = 30) and ALL (n = 16); retrospective,
multicenter
DLI (n = 19) or second allo- HCT (n =
cytoreductive CTx
AML (n = 184), MDS (n = 69), and other malig-
nancies (n = 161); retrospective, multicenter
DLI with or without preceding CTx
AML/MDS (n = 100); retrospective,
monocenter
CTx (n = 73) versus HMA (n = 27); D
in CTx group; n = 9 in the HMA grou
BSC indicates best supportive care; HMA, hypomethylating agents.by a predominant donor chimerism, has been achieved. In the
majority of studies reported to date, DLI has been administered
after discontinuation of immunosuppression and in the
absence of GVHD or severe infections.
Although there is a lack of actual dose-finding studies, a
higher starting dose of 5 to 10£ 106 CD3+/kg is usually chosen
for preemptive and therapeutic DLI. Based on the experience
in numerous studies, this dose may yield higher efficacy but is
also associated with a higher risk of GVHD. DLI can then be
repeated in escalating doses based on response and the occur-
rence of GVHD.
Several studies have explored the combination of DLI with
chemotherapy [128]. Here DLI is administered either at the
time of the leukocyte nadir or after a response is achieved with
regenerated bone marrow function. The former approach is
attractive because it does not require sustained response, but
it carries a higher risk of toxicity. The latter approach holds
promise for better response and less GVHD risk but might not
be appropriate in some patients owing to a lack of sustained
response.
A promising approach is the repeated application of hypo-
methylating agents followed by DLI as described above
[106,108]. Based on the rationale that hypomethylating agentsMain Findings Reference
) partially 2-yr OS: DLI, 20% versus CTx, 9% (P< .01); better




Long-term OS almost exclusively in patients who
achieved CR after CTx and received DLI or 2nd
HCT
[14]
LI 56% GVHD; 2-yr OS, 19%; patients with CR, 1-yr
OS, 51%
[137]
e (n = 13)
wed by
CT (n = 70)
Similar better 1-yr OS with CTx followed by DLI
(53%) or by second allo-HCT (51%) compared with
CTx alone (28%), DLI alone (15%), or BSC (5%)
[126]
27) after Similar outcomes for DLI or 2nd allo-HCT; inter-
val from 1st allo-HCT to relapse the only factor
impacting OS
[138]
CR at day +100 post-DLI: AML, 17%; MDS, 30%;
factors associated with response in entire group:
GVHD, molecular/cytogenetic relapse compared
with hematologic relapse
[127]
LI (n = 41
p)
Median OS: 6 mo in CTx group versus 3.9 mo in
HMA group (P < .01); CTx + DLI with best out-
come: 1-yr OS, 44%; median OS, 9.8 mo
[111]
Table 4







Phase I Study of Single-Agent and Combined Checkpoint Inhibition after
Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High
Risk for Post-Transplant Recurrence
ClinicalTrials.gov NCT02846376
AML, MDS, Hodgkin lymphoma,
B-NHL 26 Pilot study
Pilot Study of Pembrolizumab Treatment for Disease Relapse after Alloge-





Phase 2 Study of Ponatinib (Iclusig) for Prevention of Relapse after Alloge-






A Phase I Study of the Tumor-Targeting Human F16IL2 Monoclonal Anti-
body-Cytokine Fusion Protein in Combination with the Anti-CD33 Anti-
body BI 836858 in Patients with AML Relapse after Allogeneic





Phase I Dose Escalation Study of Velcade in Combination with Lenalido-
mide in Patients with Relapsed Acute Myeloid Leukemia (AML) and Mye-





A Phase I Study of Nivolumab in Combination with Ipilimumab for the
Treatment of Patients with High-Risk or Refractory/Relapsed Acute Mye-





A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leu-
kemia Patients with High Risk of Post-Allogeneic Stem Cell Transplanta-
tion Relapse
PF-04449913 Is a Small Molecule Inhibitor of the Hedgehog (Hh) Pathway
That Inhibits the Protein Smoothened (SMO)
ClinicalTrials.gov NCT01841333
MDS, CMML, and sAML
50
Phase II
Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition
to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment
of Patients with MDS, CMML or AMLWho Relapse after Allogeneic Stem
Cell Transplantation
ClinicalTrials.gov NCT02472691
AML, JMML, ALL, and CML
24
Phase I
Phase I Study of Adoptive Immunotherapy with CD8+ and CD4+ Memory T
Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for
Children and Adults with Recurrent Acute Leukemia after Allogeneic





Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion
in Patients with Relapsed Acute Myeloid Leukemia Post-Allogeneic





European Intergroup Trial on Panobinostat Maintenance after HSCT for
High-Risk AML and MDS: A Randomized, Multicenter Phase III Study to
Assess the Efficacy of Panobinostat Maintenance Therapy versus Standard
of Care Following Allogeneic Stem Cell Transplantation in Patients with





A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III
Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Ther-
apy Following Allogeneic Transplant for Patients with FLT3/ITD AML
ClinicalTrials.gov NCT02997202
B-NHL, B cell non-Hodgkin lymphoma; CML, chronic myelomonocytic leukemia; JMML, juvenile myelomonocytic leukemia.
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ducted in patients with AML relapse in which chemotherapy
was followed by DLI and then azacytidine [105]. Given the lack
of a typical and targetable antigen, no valid data on chimeric
antigen receptor (CAR) T cell therapy for MDS and AML are yet
available, but trials are ongoing.
Taken together, the available data indicate that preemptive
and therapeutic DLI are effective in AML/MDS and can be rec-
ommended alone or in combination with other agents when
predominant donor chimerism has been achieved, depending
on the individual disease burden and GVHD risk.Conventional Chemotherapy to Induce Remission
In cases of overt relapse, a conventional chemotherapy can
be applied to reduce the tumor burden. However, chemother-
apy alone generally has no curative potential in this setting.
Thus, intensive chemotherapy with the goal of inducing remis-
sion is justified if a subsequent consolidation treatment, such
as DLI or second allo-HCT, is feasible. Dosage adjustments may
be necessary based on bone marrow function, and in general,
greater toxicity should be expected. A retrospective study sug-
gested that immunotherapy including second allo-HCT or DLIis superior to chemotherapy alone in relapsed MDS after allo-
HCT; OS was 32% in the immunotherapy group, 6% in the cytor-
eductive chemotherapy-only group, and 2% in the palliative
care-only group (P < .001) [129].
Taken together, the foregoing findings suggest that aggres-
sive remission induction chemotherapy is recommended in
AML/MDS relapse after allo-HCT for those patients who are
likely to tolerate the toxicity and are eligible for subsequent
treatment with either DLI or second allo-HCT.Second Allo-HCT
Like DLI, second allo-HCT is an alternative strategy to facili-
tate a GVL effect. A retrospective registry study of 179 patients
demonstrated that a second allo-HCT for relapsed leukemia
including AML is feasible, yielding a 2-year OS of 25% [130]. A
separate case series of patients conditioned with RIC for second
allo-HCT reported a transplantation-related mortality of 31%
and a 3-year OS of 18% [131]. Survival after second allo-HCT is
correlated with low disease burden at the time of second allo-
HCT, longer remission after first allo-HCT, and younger age
[132]. The available data also show that a change of donor is nei-
ther favorable nor unfavorable [132]. In a retrospective analysis
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second allo-HCT and DLI found no difference in OS at 2 years
(26% versus 25%) or 5 years (19% versus 15%) [133]. For both
approaches, OS was significantly better in patients who were in
CR before the intervention and who experienced relapse more
than 6 months after first allo-HCT [133]. Recent data suggest
that, given the higher incidence of HLA loss in relapse after hap-
loidentical donor allo-HCT, a new donor with a different HLA
mismatch may be preferable [23].
Nonetheless, there is no prospective evidence suggesting a
superior outcome with second allo-HCT compared with DLI.
Given the sparse data, as well as the ongoing improvements in
allo-HCT techniques, the decision regarding a second allo-HCT
should be individualized for each patient.
Specific Aspects of Supportive and Palliative Care
Transfusions and antimicrobial prophylaxis should be pro-
vided based on the established principles for patients after
allo-HCT. This includes the need for irradiation of blood prod-
ucts to prevent transfusion-associated GVHD in this era of
inline-filtrated blood products, as well as prophylaxis for infec-
tions with viruses and encapsulated pathogens.
Treatment of Specific Conditions
Chloroma, or granulocytic myelosarcoma, is a solid tumor
composed of AML blasts. Chloroma poses a specific challenge
because it often occurs at immunoprivileged sites, such as the
central nervous system, skin, and bones, which are believed to
be less accessible for the GVL effect. However, ipilimumab
treatment was shown to be effective in patients with chloroma
[34], suggesting that immune checkpoint inhibition may help
counteract the immune escape at immunoprivileged sites. Spe-
cific targeting approaches may offer new options [134]. Radia-
tion either in palliative doses or in combination with systemic
therapy may be justified to relieve organ compression.
Specific Approaches in Pediatric and Adolescent Patients
The number of patients age <18 years with AML undergo-
ing allo-HCT is very small. Approximately 25% of these patients
experience an overt relapse after allo-HCT. These low patient
numbers have hindered conclusive studies, and standards
have not yet been defined. A retrospective international data-
set including more than 300 pediatric patients is currently
being evaluated. Preliminary data suggest a low likelihood of
long term survival without a second allo-HCT (personal com-
munication, M. G. Sauer). Given their retrospective nature,
these data are prone to a strong selection bias, and subgroups
of patients may benefit from targeted approaches.
SUMMARY AND OUTLOOK
Relapse remains the most challenging cause of treatment
failure after allo-HCT. Approaches to reduce relapse risk by
increasing the intensity of the conditioning regimen or reduc-
ing immunosuppression with the aim of increasing the GVL
effect carry a substantial risk of severe complications. There-
fore, these interventions should be chosen individually based
on relapse risk and patient-related factors, such as age and
comorbidities.
Prophylaxis to reduce the risk of relapse after allo-HCT
includes both pharmacologic and cellular approaches. Both
strategies can reduce the risk of relapse but carry the risk of
side effects in a fraction of “already cured” individuals. In con-
trast, preemptive interventions based on the detection of MRD
or mixed chimerism as well as the treatment of overt hemato-
logic relapse affects only patients with a very poor long-termprognosis. Besides symptomatic treatment and palliative che-
motherapy, some new approaches offer long-term remission
and even cure in a substantial number of patients. These treat-
ment strategies have evolved in recent years, and most com-
bine cytotoxic or disease-specific targeted therapy with
cellular approaches to break tolerance and augment the GVL
effect. Although relapse of AML and MDS after allo-HCT
remains a therapeutic challenge, multiple promising therapeu-
tic approaches have evolved over the past decade, including
TKIs, cellular therapy techniques, hypomethylating agents,
small molecules, and immune checkpoint antibodies. Cellular
therapies based on CAR technology are intriguing, allowing
leukemia rejection without eliminating healthy progenitor and
stem cells. TKIs directed at FLT3, immune-modulating agents
like lenalidomide, and immune checkpoint inhibitors against
CTLA4 and PD1 are promising agents but carry a risk of severe
GVHD. Ultimately a second or subsequent allo-HCT may be
performed in eligible patients.
Future studies focusing on post-transplantation MRDmoni-
toring and early treatment of relapse or persistent disease are
needed, to facilitate treatment of patients at risk and spare
patients not requiring intervention from the side effects of
treatment. A better understanding of the mechanisms respon-
sible for the persistence of LSCs in the bone marrow will lead
to identification of molecular targets of treatment.
Here we have provided the treating physician with an over-
view of the published evidence on the use of classical thera-
peutic strategies and novel therapeutic targets currently being
tested in clinical studies to prevent and treat relapse of AML
and MDS after allo-HCT. Further improving the prognosis of
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